AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The company’s technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viral pathogens for immunocompromised patients under viral attack. AlloVir’s technology and manufacturing process enables the potential for the treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
Company Details
- Employees
- 17
- Address
- 1100 Winter Street, Waltham,ma 02451,united States
- Phone
- (346)772-0319
- in****@****yte.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- allovir.com
- HQ
- Waltham, MA
Allovir Questions
Allovir's helpline number is (346)772-0319
Allovir's website is allovir.com
Allovir's LinkedIn profile is https://www.linkedin.com/company/allovir
Allovir has
17 employees.
View email and phone details for 17
employees at Allovir.
Allovir's industry is
Biotechnology Research
Allovir's top competitors are
Elevatebio,
Uniqure,
Kadimastem Ltd.,
Viking Therapeutics, Inc.,
Beam Therapeutics,
Ascendis Pharma,
Nls Pharmaceutics Ag,
Ernexa Therapeutics,
Neurogene Inc.,
Kalaris Therapeutics.
Allovir's support email address is info@viracyte.com
Allovir's categories are Biotechnology Research
